Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Correspondence to Dr Georgia Mavria, Signal Transduction and Tumour Microenvironment Group, Leeds Institute of Cancer and Pathology ... is characterised by tissue fibrosis and vasculopathy with ...

Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, New York, USA; daniela.sia{at}mssm.edu Objective The diversity of the tumour microenvironment (TME) of intrahepatic ...

State Key Laboratory of Silicon and Advanced Semiconductor Materials, School of Materials Science and Engineering, Zhejiang University, Hangzhou 310058, China ...

Bicara is developing ficerafusp alfa, a first-in-class, dual-action bifunctional epidermal growth factor receptor (EGFR)/transforming growth factor beta (TGF-β ... blocking both cancer cell-intrinsic ...

For instance, the team discovered that non-cancerous cells bordering cancer cells were in a unique state driven by transforming growth factor-beta (TGF-β) signaling, a critical pathway involved ...

While novel and more effective treatments continue to increase at a rapid rate, testing platforms that accurately mimic the tumor microenvironment (TME) are lacking. Tumors are complex ecosystems that ...

Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei 230601, China Clinical Research Unit, Changhai Hospital, Naval Medical University, Shanghai 200433, China ...

An immuno-oncology targeting panel accurately characterized tumor-resident immune cells and located pathologically and clinically relevant tumor microenvironment features. Cancer development and ...